Website: http://www.spybiotech.com/
Develops innovative techniques to create vaccines by utilizing cutting-edge technology and research for improved immunization solutions.
VentureRadar Research / Company Website
SpyBiotech is a spin-out from the University of Oxford pioneering a powerful new approach to generate vaccines. SpyBiotech have developed unique technology to transform how vaccines are created. Features: Unique access to protein superglue for vaccines: SpyTag/SpyCatcher; Rapid and irreversible linkage of antigen to virus-like particle platform; Specific assembly to give an optimal focused immune response; Applicable to a wide range of infectious diseases (viral, bacterial, parasitic) and potentially to cancer.
VentureRadar Research / Company Website
Associated sectors:
Life Sciences; Biotech; Biotechnology; Therapeutics; VLP Vaccine; Vaccines; Oncology; Infectious diseases; Antimicrobial Resistance; Health; Medical;
Similar Companies:
Vaccitech
United Kingdom
Publicly Traded
Vaccitech is a spin-out company from the University of Oxford’s Jenner Institute, one of the oldest and most renowned vaccine research centres in the world. We develop leading T cell-inducing vaccine products to improve global health. Vaccitech is engaged in Phase 2 clinical programs for universal influenza and prostate cancer, Phase 1 for MERS, and preclinical programs for 3 other therapeutic infectious diseases indications.
GEOVAX, INC.
USA
Publicly Traded
GeoVax is developing the next generation of vaccines and immunotherapies to address unmet medical needs in cancer and infectious disease. Our current development programs are focused on vaccines against Human Immunodeficiency Virus (HIV), Hemorrhagic Fever viruses such as Ebola (Zaire, Sudan), Marburg and Lassa, Malaria and Zika virus. We have also initiated programs to develop a multi-antigen vaccine to treat chronic Hepatitis B (HBV) infections, a vaccine to treat human papilloma virus (HPV)-induced cancers and a vaccine against tumor associated antigen MUC1 that is associated with metastic progression of many cancer types including breast, ovarian, gastric, liver, pancreas, renal and lymph nodes.
Celestial Therapeutics
USA
Privately Held
Celestial Therapeutics Inc. is a new California biotech developing novel proteins for treatment of infectious diseases and inflammatory conditions. Focus is new drugs for treating respiratory infections that have limited treatments. Lead product is a therapeutic protein with broad-spectrum anti-viral properties. First use will be for treatment of lung infections caused by Respiratory Syncytial Virus (RSV) and Influenza Virus.
20Med Therapeutics
Netherlands
Privately Held
20Med Therapeutics is a Dutch biotechnology company focused on the development of prophylactic and therapeutic vaccines. Based on its proprietary bioresponsive polymer nanoparticle technology 20Med is building a non-viral delivery platform for the rapid development of RNA and DNA based vaccines, with applications in infectious diseases and cancer.
Delonix Bioworks
China
Privately Held
Delonix Bioworks is working on synthetic biology approaches to develop the next generation medical solutions for infectious diseases and cancer; current lead programs target antimicrobial resistance (AMR). Delonix Bioworks' antigen discovery and synthetic biology platforms enable rational design and programming of bacteria into more safe and effective vaccines.
Virometix
Switzerland
Privately Held
Virometix AG is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases. Virometix exploits the tools traditionally used in drug discovery, rational molecular design and chemical synthesis, for the generation of structurally optimized Synthetic Antigen Mimetics (SAMs) along with its proprietary Synthetic Virus-Like Particle (SVLP) platform technology for delivery of SAMS to immune system cells. With its uniquely positioned SVLP and SAM platform technologies, Virometix aims to establish a new benchmark in the design of synthetic vaccines and nanomedicines.